Moa Fransson

Director/Board Member at ENZYMATICA AB

Net worth: 4 036 $ as of 2026-05-30

Health Technology

Consumer Services

Profile

Moa Fransson is the founder of Bioflow Systems AB. Dr. Fransson is the Chief Executive Officer of Mesenkia Therapeutics AB since 2024, the Chief Executive Officer of Genagon Therapeutics AB since 2019, and the Director of Enzymatica AB since 2022.
Dr. Fransson holds a doctorate from the University of Uppsala.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
ENZYMATICA AB 0.01%	2024-12-30	13,652 ( 0.01% )	4 036 $	2026-05-30

Moa Fransson active positions

Companies	Position	Start
ENZYMATICA AB	Director/Board Member	2022-04-30
Genagon Therapeutics AB Genagon Therapeutics AB BiotechnologyHealth Technology Provides scientific and technical research and development services	Chief Executive Officer	2019-11-30

All active positions of Moa Fransson

Former positions of Moa Fransson

Companies	Position	End
Bioflow Systems AB	Founder	-

See the detail of Moa Fransson's experience

Training of Moa Fransson

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Moa Fransson's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	4
University of Uppsala University of Uppsala Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Enzymatica AB Enzymatica AB Medical SpecialtiesHealth Technology Develops and sells medical technology products against infectious diseases	Health Technology
Genagon Therapeutics AB Genagon Therapeutics AB BiotechnologyHealth Technology Provides scientific and technical research and development services	Health Technology
Bioflow Systems AB